Pathogen inactivation of red cell concentrates and whole blood: I. History, technologies and in vitro product preservation studies.

ABSTRACT: The application of technologies to inactivate pathogens in pooled plasma products is nowadays the standard. The number of blood centres applying these technologies to platelet concentrates is steadily increasing. However, pathogen inactivation (PI) of red cell concentrates and whole blood (WB) is challenging, as the haemoglobin-containing red cells quench light, and therefore require a different approach. Three technologies are currently under active development: S-303 (Intercept), UV-C (Theraflex) and riboflavin/UV (Mirasol). The S-303 technology is used for PI of red cell concentrates and has seen significant technical and clinical development in the last decade. Using this technology, red cell both ATP and haemolysis levels conform to objective requirements. For the UV-C technology, onl

SUBMITTER: van der Meer PF 

PROVIDER: S-EPMC12926800 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature